🎉 Surprise earnings release has this small cap soaring

What you need to know                                                                                                                                                                                                                                                                                                                                                                                                                 April 16, 2024 🎉 Surprise earnings release has this small cap soaring Today's sponsor Good morning, 360! Please join us [TODAY at 2pm EST for a special interview]( with Don Kaufman — of Think or Swim fame. All are welcome! FOCUS LIST🔎 DFLI - Up over 60% in the pre-market after reporting positive Net Income CGEM - Up over 20% in pre after $280 million oversubscribed private placement and strategic expansion into Autoimmune Diseases ITCI - Up over 20% in pre after positive Phase 3 results in Major Depressive Disorder therapy JOIN US TODAY 2PM EST Special Interview with Mr. Don Kaufman of Think of Swim Fame [Live in the Market Master’s Room]( Don is one of the industry's LEADING financial strategists and educational authorities. Here’s a taste of what we'll be serving up: 1. Volatility is at a very recent high 2. The market is frothy with overbought stocks 3. The trading setup to capitalize is already set up and the class to learn is waiting for you to take. [Join us HERE @ 2ET]( to get in on the next trading wave! HOTLIST🔥 DFLI - Up over 60% in the pre-market after reporting positive Net Income Dragonfly Energy Holdings Corp. (DFLI) manufactures and supplies deep cycle lithium-ion batteries for recreational vehicles, marine vessels, off-grid installations, and other storage applications. In the after-hours yesterday, [the company reported]( Q4 and full year 2023 results. The main highlight of the earnings release was the company reporting Net Income of $3.0 million, compared to a Net Loss of $(32.5) million in Q4 2022. The market cheered the result as DFLI traded up over 60% in the pre-market following the earnings report. The $0.6850 area has acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $0.78, $0.86, $0.94 and then the pre-market high at $1.03. Beyond that, $1.10 and $1.20 come into play. Below $0.6850, targets to the downside are $0.60, $0.50 and then a gap fill at $0.45. CGEM - Up over 20% in pre after $280 million oversubscribed private placement and strategic expansion into Autoimmune Diseases Cullinan Oncology, Inc. (CGEM) is a biopharmaceutical company that focuses on developing oncology therapies for cancer patients in the United States.’ In the pre-market this morning, the [company announced]( that it has entered into a stock purchase agreement with certain institutional and accredited investors for a private placement of approximately $274.0 million of shares of its common stock at a price of $19.00 per share and, in lieu of common stock to certain investors, $6.0 million of pre-funded warrants to purchase shares of its common stock at a price of $18.999 per pre-funded warrant. The exercise price of each pre-funded warrant will equal $0.001 per share. CGEM also [announced a strategic expansion]( into Autoimmune Diseases. The stock traded up over 20% in the pre-market after the news. $19 was a prior resistance area and now becomes potential support. Above it, targets to the upside are $19.80, $20.20 and then the pre-market high at $20.47. Beyond that $22 and $23.82 come into play. Below $19, targets to the downside are $18, $16.32, and $16. *sponsored by MaxAI [MaxAI.me -]([Transform Browsing with AI Magic]( [MaxAI.me]( turns every click into AI magic. Instantly summarize articles, craft emails, and search the web with AI. #1 of the day and the week on ProductHunt. [Join 1M+ users transforming their online efficiency. Install now!]( ITCI - Up over 20% in pre after positive Phase 3 results in Major Depressive Disorder therapy Intra-Cellular Therapies, Inc. (ITCI) is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. In the pre-market this morning, the [company announced]( positive topline results from Study 501 evaluating lumateperone 42 mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD). Lumateperone 42 mg met the primary endpoint of change from baseline at Week 6 on the Montgomery-Åsberg Depression Rating Scale (MADRS) total score versus placebo (4.9 point reduction v. placebo; p<0.0001; Cohen’s d effect size (ES)= 0.61) In this study, lumateperone 42 mg robustly improved depressive symptoms as reported by patients as measured by the Quick Inventory of Depressive Symptomatology Self Report (QIDS-SR-16) (p<0.0001). The QIDS-SR-16 is a 16-item patient-rated scale of symptom severity in depression. It assesses nine key symptoms of depression: insomnia/hypersomnia, low mood, appetite/weight changes, impaired self-perception, concentration difficulties, loss of interest/pleasure, suicidal ideation, psychomotor agitation and fatigue. The stock traded up over 20% in the pre-market after the results. The $75.75 area has acted as support in the pre-market and will be an important level to watch. Above it, targets to the upside are $78.90, and then the pre-market high at $86.86. Beyond that is all-time high and round numbers such as $90 and $100 come into play. Below $75.75, targets to the downside are $74, $70, $67 and a gap fill at $64.76. MARKET NEWS 📰 P.S. Make sure you text “RAGE” to (888) 404-5747 to get all of our latest HOT STOCK ideas! Questions or concerns about our products? Email [Support@360wallstreet.io]( © Copyright 2022, RagingBull DISCLAIMER: To more fully understand any Ragingbull.com, LLC ("RagingBull") subscription, website, application or other service ("Services"), please review our full disclaimer located at . FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. AnyRagingBull Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RagingBull strongly recommends you consult a licensed or registered professional before making any investment decision. RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RagingBull Services may contain information regarding the historical trading performance of RagingBull owners or employees, and/or testimonials of non-employees depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, subscribers' trading results have NOT been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment. RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RagingBull nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization. WE MAY HOLD SECURITIES DISCUSSED. RagingBull has not been paid directly or indirectly by the issuer of any security mentioned in the Services except possibly by advertisers mentioned in this email. However, Ragingbull.com, LLC, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication. *Sponsored Content: If you purchase anything through a link in this email other than RagingBull services, you should assume that we have an affiliate relationship with the company providing the product or service that you purchase, and that we will be paid in some way. We recommend that you do your own independent research before purchasing anything. We believe in the companies we form affiliate relationships with, but please don’t spend any money on these products or services unless you believe they will help you achieve your goals. RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RagingBull.com, LLC and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RagingBull.com, LLC shall be entitled to recover attorneys’ fees, costs and disbursements in addition to any other relief to which it may be entitled. [tw]( Update your email preferences or unsubscribe [here]( © 2024 360 WallStreet 62 Calef Hwy. #233 lee, NH 03861, United States of America